Safety and efficacy profle of Trastuzumab deruxtecan in solid cancer: Pooled reanalysis based on clinical trials
Số trang: 9
Loại file: pdf
Dung lượng: 828.52 KB
Lượt xem: 17
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
This study aimed to explore the efficiency and safety of the new generation antibody-drug conjugate Trastuzumab deruxtecan (DS-8201a) in treating HER2-positive solid cancers. By searching PubMed, Medline and Ovid for all clinical trials related to the safety and efficacy of DS-8201a. Event rates were calculated for all adverse events (AEs) to evaluate the safety of DS-8201a. Objective response rate (ORR) and progression-free survival (PFS) were summarized to assess the potency of DS-8201a.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Trastuzumab deruxtecan Adverse events Progression free survival Human epidermal growth factor receptor 2 Breast cancer Gastric cancerGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 166 0 0 -
6 trang 165 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 138 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 106 0 0 -
12 trang 86 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 35 0 0
-
11 trang 34 0 0
-
12 trang 33 0 0